Okava测试猫在猫体内植入GLP-1,以对抗肥胖症,预计2026年夏季将取得结果。 Okava tests a GLP-1 implant in cats to fight obesity, with results expected by summer 2026.

奥卡瓦制药公司正在测试一个以GLP-1为基础的植入器(OKV-119),在一项名为MEOW-1的临床试验中,该试验涉及50只猫,目的是防治肥胖症,这一疾病影响到大约60%的美国猫,并增加了糖尿病和其他健康问题的风险。 Okava Pharmaceuticals is testing a GLP-1-based implant, OKV-119, in a clinical trial called MEOW-1 involving 50 cats to combat feline obesity, a condition affecting about 60% of U.S. cats and increasing risks for diabetes and other health issues. 为期六个月的植入手术旨在提高胰岛素的敏感性,并在不改变喂养习惯的情况下减少脂肪重量。 The six-month implant aims to improve insulin sensitivity and reduce fat mass without changing feeding habits. 预计在明年夏天得到结果, 两年内获得FDA批准. Results are expected by next summer, with FDA approval sought within two years. 对狗的类似治疗也在发展中。 A similar treatment for dogs is also in development. 如果获得批准,月费用可能为100美元左右,但副作用和长期效力方面仍存在不确定性。 If approved, the monthly cost could be around $100, though uncertainties remain about side effects and long-term effectiveness.